These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Laser treatment of imipramine-induced hyperpigmentation. Atkin DH; Fitzpatrick RE J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):77-80. PubMed ID: 10863228 [TBL] [Abstract][Full Text] [Related]
6. Novel hyperpigmentation pathophysiology following a prolonged course of imipramine therapy. McKenna B; Wold L; Noland MM; Schenck O J Cutan Pathol; 2024 Feb; 51(2):105-107. PubMed ID: 37818708 [TBL] [Abstract][Full Text] [Related]
7. Delayed darkening of imipramine-induced hyperpigmentation after treatment with a Q-switched Nd:YAG laser followed by a Q-switched ruby laser. Izikson L; Anderson RR Dermatol Surg; 2009 Mar; 35(3):527-9. PubMed ID: 19250303 [No Abstract] [Full Text] [Related]
8. Imipramine-Induced Cutaneous and Iris Hyperpigmentation: A Case Report and Literature Review. Coffey N; Ali Z; Grau J Prim Care Companion CNS Disord; 2022 Mar; 24(2):. PubMed ID: 35364629 [No Abstract] [Full Text] [Related]
9. Tobacco Consumption Concerns With the Use of CYP1A2 Metabolized Antidepressants. Gressier F; Rotenberg S; Ait Tayeb AEK; Colle R; Hardy P; Becquemont L; Verstuyft C; Corruble E Am J Psychiatry; 2015 Sep; 172(9):909-10. PubMed ID: 26324305 [No Abstract] [Full Text] [Related]
10. Photodistributed blue-gray pigmentation of the skin associated with long-term imipramine use. Angel TA; Stalkup JR; Hsu S Int J Dermatol; 2002 Jun; 41(6):327-9. PubMed ID: 12100685 [TBL] [Abstract][Full Text] [Related]
11. Mirtazapine and hyperpigmentation. Mendhekar D; Inamdar A World J Biol Psychiatry; 2009; 10(4 Pt 2):688-9. PubMed ID: 19404867 [No Abstract] [Full Text] [Related]
12. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder. Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044 [TBL] [Abstract][Full Text] [Related]
13. Tricyclic-induced musical hallucinations and states of relative sensory deprivation. Terao T Biol Psychiatry; 1995 Aug; 38(3):192-3. PubMed ID: 7578664 [No Abstract] [Full Text] [Related]
14. Imipramine-induced facial pigmentation: case report and literature review. Metelitsa AI; Nguyen GK; Lin AN J Cutan Med Surg; 2005 Dec; 9(6):341-5. PubMed ID: 17016757 [TBL] [Abstract][Full Text] [Related]
15. Tricyclic drugs in the treatment of depression. Glassman AH; Roose SP Med Clin North Am; 1982 Sep; 66(5):1037-45. PubMed ID: 6752599 [No Abstract] [Full Text] [Related]
16. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Pancheri P; Scapicchio P; Chiaie RD Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028 [TBL] [Abstract][Full Text] [Related]
17. Imipramine-induced hyperpigmentation: a case report and review of the literature. D'Agostino ML; Risser J; Robinson-Bostom L J Cutan Pathol; 2009 Jul; 36(7):799-803. PubMed ID: 19519613 [TBL] [Abstract][Full Text] [Related]
18. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. van den Broek WW; Birkenhäger TK; Mulder PG; Bruijn JA; Moleman P Psychopharmacology (Berl); 2004 Oct; 175(4):481-6. PubMed ID: 15243735 [TBL] [Abstract][Full Text] [Related]
19. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. Siwek M; Dudek D; Schlegel-Zawadzka M; Morawska A; Piekoszewski W; Opoka W; Zieba A; Pilc A; Popik P; Nowak G J Affect Disord; 2010 Nov; 126(3):447-52. PubMed ID: 20493532 [TBL] [Abstract][Full Text] [Related]
20. Possible interaction between imipramine and butalbital. Garey KW; Amsden GW; Johns CA Pharmacotherapy; 1997; 17(5):1041-2. PubMed ID: 9324197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]